MYC and cancer: Bromodomain and extraterminal (BET) inhibitors have been developed as anti-cancer drugs due to their roles in cell cycle regulation and RNA polymerase II (Pol II) transcription, including initiating transcription of proto-oncogenes including c-MYC (1–3).